Abry Partners closed an oversubscribed $780 million continuation vehicle for Centauri Health Solutions, letting the Boston‑based manager retain a top‑line healthcare asset. The fund, co‑led by Neuberger Private Markets and Apollo’s Sponsor and Secondary Solutions (Apollo S3), offers existing limited partners liquidity or rollover options while pulling new capital for the business’s next growth phase.

GP‑led secondaries have become a favored tool for private‑equity firms seeking to extend ownership without a full exit. For Abry, the structure avoids selling a proven revenue generator and preserves upside as Centauri expands its managed‑care contracts. Fresh commitments also signal confidence from secondary investors in the firm’s long‑term health‑care strategy.

The vehicle’s oversubscription underscores strong demand for stable, cash‑generating health‑care platforms. By keeping Centauri within its portfolio, Abry positions itself to benefit from anticipated payer‑mix improvements and regulatory tailwinds. The deal illustrates how GP‑led continuations can lock in value while supplying fresh capital for portfolio growth.

Investors in the continuation fund gain exposure to Centauri’s $1.5 billion revenue base and its expanding suite of specialty pharmacy services. The partnership with Neuberger and Apollo also broadens the secondary market’s capacity to recycle capital efficiently. Overall, the transaction demonstrates a maturing secondary market that can sustain large‑scale GP‑led financings.